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By Ben Wilson 
Abstract 
Over the past 25 years, new antimicrobial discovery has ground to a halt, this combined 
with a rise in antimicrobial resistance in pathogenic bacteria, is causing the number of 
effective treatments available to humankind decrease. 
For my thesis, I explored the testing methods for screening antimicrobial compounds and 
found them to be inefficient. One of the limiting factors for the discovery of new antimicrobial 
compounds are the efficacy testing assays and high-throughput screening methods used 
by researchers. These methods mainly measure the ability of a compound to diffuse 
through or across a medium, be it agar, filter papers or testing strips. 
Within this thesis I developed new testing assays for a family of novel antimicrobials, as 
their efficacy wasn't measurable by the standard procedures. I also measured the MIC50 
and MIC100 values of all the compounds in the group. They had measurable antimicrobial 
effect against Gram-Positive bacteria - comparable with established compounds like 
Vancomycin, and measurable interaction with Gram-Negative bacteria, coating the cells 
and inhibiting growth. 
I then further explored the coating interaction, adding the compounds to bacteria, but also 
adding solutions of established antimicrobials, I found that the compound boosted the 
efficacy of the established compounds and was also able to overcome resistance 
mechanisms developed by the bacteria. 
Finally, I developed a modular, 3D printed robot to standardise and increase the accuracy 
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 Medical Significance of Antibacterial Resistance 
The worldwide library of clinically effective antimicrobials is becoming increasingly limited, 
this is due to a rise in antimicrobial resistance (AMR) exhibited by bacteria 1. The deaths 
due to resistant disease causing bacteria are projected by the World Health to rapidly 
increase within the next 30 years (Figure 1). This is due to three things: the misuse of 
antimicrobials causing a development of resistance by bacterial organisms, the 
development of antibacterial resistance within agriculture, and the slowing of novel 
antibacterial discovery 2. The human race can take action against two of these factors; 
stopping the misuse of antibacterials through education and stricter rules on prescription, 
and developing novel methods of antibacterial discovery and screening. Meanwhile, 
bacteria will still continue to develop resistance to known antibacterial compounds, so 
compounds with novel mechanisms of action must be investigated and developed 3. 
 
FIGURE 1 - CHART SHOWING DEATHS RELATED TO ANTIBACTERIAL RESISTANCE IN COMPARISON TO OTHER 
MAIN CAUSES, PROJECTED DEATHS FROM RESISTANT BACTERIAL INFECTIONS WILL OUTNUMBER THE DEATHS 









Deaths from antimicrobial resistance every year compared to 
the other major causes of death
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 Misuse of antibacterials 
The misuse of antibacterials is comprised by two problematic behaviours; misprescription 
of the antibacterial drugs, and improper use of the prescribed drugs. The main 
misprescription issues are caused by medical professionals unnecessarily prescribing 
broad spectrum antibacterial therapies such as ampicillin and amoxicillin. The improper use 
of the prescribed drugs is facilitated by patients not completely finishing full courses of 
antibacterials, rather stopping when their symptoms are alleviated, this greatly reduces the 
chance of the target microorganism being eradicated, and increases the likelihood that the 
remaining population is equipped with modified characteristics that grant them resistance 
to the therapy 5±7. 
Another area where antibacterials are abused is in agriculture. In both first and third world 
settings, antibacterials are added to the foodstuffs of livestock to promote growth and 
prevent contraction of infectious disease, an estimated 70% of all antibacterial compounds 
sold in the USA are used for this purpose 8. Detection methods have recently shown that 
resistant bacteria are passed to humans through the ingestion of farmed meat. This is 
because the livestock act like breeding incubators for resistance, with the ingested 
antibacterials acting as the selection pressure, killing off most of the bacterial population, 
and leaving the cells that are resistant. This small population of bacteria will thrive in the 
body of the host, and be contained within the meat after it is killed and processed 9,10. Many 
pathogens such as Listeria and Campylobacter are incubated within livestock, but the most 
prevalent are drug resistant strains of Staphylococcus aureus 11. The use of antibiotics in 
agriculture also effects the environmental microbiome. Around 90% of antibacterials 
ingested by livestock are excreted in urine and faeces12. These excretions are then 
distributed around the environment by human and natural means. Humans gather up the 
faeces produced by livestock and spread them on fields as fertilisers. The compounds will 
leach into the surroundings, accelerated by natural processes like precipitation and surface 
runoff. This exposes microorganisms in the environment to the compounds, and allows 
populations to develop resistance.  
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Lastly, antibiotic cleaning and hygiene products are adding to the misuse of antibacterials 
as they are increasing the selection pressure placed on bacterial organisms, which will lead 
to possible increased development of resistance mechanisms 13. 
 ESKAPE Pathogens 
The ESKAPE pathogens are a group of six bacterial species (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Psuedomonas 
aeruginosa, and Enterobacter) 14. These six organisms have become resistant to a large 
number of antibacterial compounds, causing a wealth of complications for the medical 
community. Prevalent in hospital wards and even operating theatres, these opportunistic 
pathogens can cause a wide variety of infections, which are particularly dangerous to 
patients in medical care due to the weak and potentially immunocompromised state they 
are in. One highlighted problem caused by ESKAPE pathogens is the formation of biofilms. 
S. aureus was first recorded forming a biofilm in 1982, the bacteria had formed a film around 
the lead of an endocardial pacemaker implanted into patient and had been causing 
persistent acute bacteraemia infections regardless of the several courses of antibiotic that 
the patient had taken 15. The persistence of S. aureus biofilms, along with any antibacterial 
resistant characteristics exhibited make them a potential infection source to anyone that 










 Mechanisms of Antibacterial Action 
Antibacterials are functionalised compounds that are prescribed to patients to combat 
infections caused by bacteria. After ingestion and reaching the target bacterial cells, the 
antibacterial compounds have several different routes of attack across the membranes of 




1.4.1 Inhibitors of cell wall synthesis. 
The most common mode of action for antibacterials is inhibiting the synthesis of the 
bacterial cell wall, most bacterial cell walls contain a peptidoglycan layer within them, this 
layer provides the cell with strength and rigidity. The peptidoglycan layer is a mesh of 
peptide and glycan chains, cross-linked covalently by a family of transpeptidase enzymes. 
The more crosslinks, the higher the strength of the cell to withstand lysis by osmosis. Drugs 
like penicillin and Cephalosporins act as pseudosubstrate mimics, and bind to the 
transpeptidases, forming complexes 16. 7KLV SUHYHQWV WKH HQ]\PH IURPXQGHUWDNLQJ LW¶V
FIGURE 2 - DIAGRAM SHOWING THE DIFFERENCES IN THE BACTERIAL CELL ENVELOPE FOR GRAM-
POSITIVE AND GRAM-NEGATIVE ORGANISMS, THE MAIN DIFFERENCE BEING THE ADDITIONAL CELL 




purpose of forming crosslinks, thus weakening the wall, and rendering the cell susceptible 
to osmotic lysis (Figure 3). The vancomycin group of antibacterials also inhibit cell wall 
synthesis, but instead of targeting the enzymes involved with the crosslinking, they target 
the substrate peptides. The vancomycin structure forms five hydrogen bonds with the 
dipeptide terminus of the pentapeptide side chain, effectively capping it. This prevents the 
enzymes from forming the cross links, and again renders the cell susceptible to osmotic 
lysis. Generally, Gram-negative bacteria are less susceptible to antibacterials that inhibit 

































FIGURE 3 - MODE OF ACTION FOR ANTIBACTERIAL COMPOUNDS THAT INHIBIT CELL WALL SYNTHESIS (PENICILLIN IN THIS EXAMPLE)63 





1.4.2 Inhibitors of protein synthesis 
The main route of attack for antibacterials that inhibit protein synthesis is ribosomal 
inhibition. Ribosomal organelles are constructed from two ribonucleoprotein subunits, the 
30s and 50s. The antibacterial compounds that inhibit protein synthesis will interact with 
either one of the subunits 17. The drugs that inhibit the 50s subunit physically block the 
initiation of protein translation, halting the peptidyltransferase process that extends the 
peptide chain. Recent study has clarified the mode of action of these compounds, stating 
that the drug prevents the binding of peptidyl tRNAs to the subunit, and stopping the growth 
of the peptide chain. Macrolide and amphenicol families of antibacterials are amongst those 
that target the 50s subunit 18. The compounds that target the 30s subunits have various 
modes of action; Tetracycline based compounds block the access of aminoacetyl tRNAs, 
and Aminocyclitols bind to sections of the rRNA causing protein mistranslation due to 
codons being altered. They can also corrupt the stability of tRNA when is binds to the 
ribosome. In the family of protein inhibiting antibacterials, the naturally produced 
aminoglycosides are the only ones that are mainly bactericidal. Macrolides, tetracyclines 
and chloramphenicols, are typically bacteriostatic, though some have exhibited bactericidal 
properties on isolated strains of microorganism.  
1.4.3 Inhibitors of nucleic acid synthesis 
Antibacterial compounds such as the quinolone and fluoroquinolone families target the 
enzymes involved in the synthesis of bacterial nucleic acids such as DNA gyrase and 
topoisomerases involved in the replication, cleaving, reattaching and coiling of the DNA 
strands 19. Quinolone based antibiotics such as ciprofloxacin bind to the complex formed 
by the DNA gyrase enzyme, and the DNA strand itself. The antibacterial stabilises the 
complex, and prevents the enzyme from removing the positive supercoiling in the DNA 
strand, this causes the bacterial DNA to fragment. This fragmentation of the DNA triggers 
the SOS repair system in the bacteria, and will ultimately lead to cell death. (Figure 4) DNA 
gyrase (or topoisomerase II) is the primary target of quinolones and fluoroquinolones within 
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Gram-negative bacteria and topoisomerase IV is the primary target of these compounds 
within Gram-positive bacteria. 
 
FIGURE 4 ± THE MODE OF ACTION OF QUINOLONE BASED COMPOUNDS ON DNA GYRASE ENZYMES, CAUSING 
FRAGMENTATION OF THE DNA STRAND. THIS CAUSES THE CELL TO TRY AND REPAIR THE BROKEN STRANDS, 
AND AS THE DRUG IS STILL PRESENT WITHIN THE CELL PREVENTING THIS REPAIR, THE CELL EVENTUALLY 





 Commercially Available Antibacterials 
1.5.1 Penicillins 
Penicillins were first discovered by Alexander Fleming in 1928. During experimentation on 
Staphylococcal bacterial strains, an inoculated plate was left out uncovered next to an open 
window. Upon revisiting it, Fleming discovered that it had been contaminated with mould 
spores. These mould spores appeared to have produced zones of inhibition on the bacterial 
lawn. Fleming isolated the mould and categorised it as a member of the Genus Penicillium, 
he extracted the excretion of the mould and tested it on various strains of bacteria. The 
QHZµ3HQLFLOOLQ¶FRPSRXQGZDVIRXQGWREHHIIHFWLYHDJDLQVW all Gram-positive pathogenic 
organisms. 
Later on, in 1940, Howard Florey and Ernst Chain took an interest in the Penicillin molecule 
and devised a method to mass produce it. This allowed Penicillin to be widely available for 
distribution during world war II 21. 
Penicillin is produced as a secondary metabolite of the Penicillium fungus when its growth 







All Penicillins contain a ȕ-Lactam ring, a four membered functionality that provides the drug 
with its antibacterial properties. This ring is also bonded to a five membered thiazolidine 
ring, causing it to become much more reactive. (Figure 5) This increased reactivity is due 
FIGURE 5 - CORE CHEMICAL STRUCTURE OF PENICILLIN BASED COMPOUNDS 
17 
 
to the steric distortion placed on the ȕ-Lactam amide bond. The mode of action for most 
Penicillins is targeting the formation of peptidoglycan crosslink formation within the bacterial 
cell wall. The drug binds to DD-Transpeptidase enzymes, preventing them from catalysing 
the reaction. This causes the cell wall synthesis to slow, and wall degradation to overtake, 
leading to cell death 22. 
1.5.2 Cephalosporins 
The first Cephalosporin based compounds were investigated during 1948 by Guiseppe 
Brotzu, he discovered a colony of Acremonium strictum growing at the outlet of a sewer 
pipe, finding that a metabolic filtrate of the mould colony produced inhibitive effects against 
the growth of Staphylococcus strains 23. 
The compounds were further developed by Edward Abraham and Guy Newton, they were 
able to isolate three versions of the Cephalosporin base molecule; P, N and C. These 
molecules were not strong enough to be used as clinical antibacterials, but after further 
investigation, the removal of their side chains yielded molecules similar in structure to 
Penicillins. This allowed Cephalosporin analogues to be produced and developed into 
clinically available antibacterials. 
Cephalosporins are ȕ-Lactam based antibacterials like Penicillins, (Figure 6) so both 
compounds share similar modes of activity, targeting the cell wall synthesis of the bacteria, 











In the late 1960s after it was observed that bacteria were producing ȕ-Lactamase enzymes 
to counteract administered Penicillins. In 1976, researchers started developing compounds 
able to inhibit ȕ-Lactamase 25. One of the observed bacterial strains was Streptomyces 
clavuligerus, which secreted products that showed ability to inhibit these enzymes, Olivanic 
acid, and Clavulanic acid. Olivanic acid was initially investigated, but found to be too 
unstable, so Clavulanic acid was investigated and then developed into the first clinical ȕ-
Lactamase inhibitor. A different strain of Streptomyces, S. cattleya, was investigated, and 
found to produce the first Carbapenem, Thienamycin. This compound still bound to the 
penicillin binding proteins produced by the bacteria it was administered to, however, its 
broad spectrum of inhibitory activity against both Gram-positive and Gram-negative 
bacteria, it was widely used, and became the template for the next generation of more 
stable clinical Carbapenems. (Figure 7) 
As with most ȕ-Lactam antibiotics, Carbapenems target cell wall synthesis, inhibiting the 





 FIGURE 7 ± CORE CHEMICAL STRUCTURE OF CARBAPENEM BASED ANTIBACTERIALS 
FIGURE 6 - CORE CHEMICAL STRUCTURE OF CEPHALOSPORIN BASED ANTIBACTERIALS 
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1.5.4 Quinolones and Fluoroquinolones 
Quinolones were first developed in the early 1960s by George Lesher and his research 
group. The compound was isolated in the by-product produced from the attempted 
synthesis of the antimalarial drug Chloroquine. This new compound, known as Nalidixic 
acid, was used to treat urinary tract infections. Over the following years, many more 
analogues were synthesised using Nalidixic acid as a structural template. 
The core structure of quinolone antibacterials is an aromatic quinolone functionality, with 
various other functionalities attached to the structure, including a carboxylic acid 
functionality at position 3 of the aromatic ring. Later generations of the quinolone 





Quinolones and Fluoroquinolones are effective against both Gram-positive and Gram-
negative EDFWHULD PDNLQJ WKHP µEURDG VSHFWUXP antibacterialV¶ :KLOVW WKLV LV
advantageous, use of all broad spectrum antibacterials can enhance the development of 
multidrug resistance within all strains of bacteria 27. 
Quinolones and Fluoroquinolones are also recorded exhibiting serious adverse side effects 
in patients they have been prescribed to. These side effects are potentially disabling, being 
linked to problems in tendons, muscles, joints and the central nervous system. There have 
been a small number of tendon rupture and tendonitis cases linked to the ingestion of 
quinolone based medications, and some of the recorded nervous system side effects have 
been recorded as being insomnia, seizures and psychosis 28. 





Tetracyclines are a class of antibacterial developed LQ WKH ¶V E\ %HQMDPLQ 0LQJH
Duggar. They exhibit antibacterial activity against a large range of organisms, including 
Gram-positive and negative bacteria, protozoans and mycoplasmas 29. They inhibit the 
protein synthesis of micro-organisms by stopping charged tRNA attaching to its 
complimentary ribosome, halting the extension of the protein chain. Tetracyclines have few 
recorded harmful side effects, this beneficial factor, coupled with the large effective range 
of the compounds, has led to wide and extensive use in the treatment of infections in 
humans and animals. Tetracyclines are also used in malaria prevention, due to its minimal 
side effects and activity against the protozoans that are becoming resistant to the quinine 
based therapies that are available. In addition to being a therapeutic antibacterial, 








All tetracyclines follow the structural pattern of a 4 piece, conjugated ring system ± 
Naphthacene 30, (Figure 9) with several functional groups connected to it. This basic 
structure can be further modified with other functional groups, alkyl chains. 
Tetracycline based drugs usually have a mode of action against the protein synthesis of 
the bacterial cell it is targeting. 





 Resistance Mechanisms 
1.6.1 Modification of the antibiotic 
Bacteria are able to resist the action of antibacterial compounds applied to them by 
targeting them and performing modifications to their structure with the help of enzymes. 
One such family of enzymes is the aminoglycoside modifying enzymes (AMEs) 31, these 
proteins have become the primary resistance mechanism for bacteria against antibacterials 
that target the protein and DNA synthesis of a bacteria. These enzymes will covalently alter 
the functional groups of antibacterials, like the amino and hydroxyl groups on the 
aminoglycoside molecule. Both Gram-positive and Gram-negative bacteria have exhibited 
production of these enzymes 32. 
Another modification performed on antibacterials by bacteria is just to destroy the molecule 
by dismantling the part of the structure that provides the antibacterial functionality. The 
primary example of this mechanism is the development of ȕ-Lactamase enzymes to combat 
ȕ-Lactam molecules 33. (Figure 10-11) These enzymes exist in several classes of differing 
structures, granting resistance to a wide range of ȕ-Lactam based antibacterials like 






FIGURE 10 (TOP) - 3D RENDERING OF BETA-





1.6.2  Efflux pumps and decreasing 
antibiotic penetration 
A large proportion of antibacterial compounds are water soluble, containing hydrophilic 
functionalities. This helps them penetrate the outer membranes of target bacteria through 
water filled diffusion channel proteins known as porins 34. As a resistance mechanism, 
bacteria have altered their genetic code to alter the characteristics of porin production within 
the cell, changing the size of the porin protein itself to prevent the influx of the compounds. 
The other modification to porin production within the cell is simply expressing less of the 
proteins, giving the antibacterial compounds less zones of access into the cell, slowing the 
mode of action. 
In addition to slowing the influx of antibacterial drugs to the cell, bacterial have also 
developed ways of increasing the efflux. Using structured membrane proteins known as 
Efflux Pumps 35, ( Figure 12) they rapidly remove compounds considered toxic to the cell. 
Efflux pumps have been observed within both Gram-positive and Gram-negative bacteria 
and exist in a multitude of classes, all of these pump proteins are active, so require a 
chemical power source, sources include ATP, positive ions and Protons. Bacterial efflux 
FIGURE 11 (LEFT) ± RING OPENING EFFECT OF 





SXPSV PXFK OLNH DQWLELRWLFV FDQ EH µEURDG VSHFWUXP¶ WDUJHWLQJ D PXOWLWXGH RI WR[LF
antibacterial compounds for removal, or they can be specifically synthesised to target one 
family of compounds, for example, Tet efflux pumps solely target compounds from the 




1.6.3 Changing target sites 
Another resistance strategy that bacterial cells employ is modifying the site that the 
antibacterials target. There are two main methods of site modification, protection and 
modification, these are caused by the modification of proteins contained within the target 
and 
ELQGLQJVLWHVE\PXWDWLRQVLQWKHFHOO¶VJHQHWLFFRGH7KHVe mutations are caused by multi-
generational selection pressures from various sources like the environment, and applied 
antibiotics. 
Target protection usually occurs against compounds that inhibit protein and DNA synthesis, 
for example, Tetracycline resistance observed in strains of Campylobacter and 
Streptococcus produces the proteins Tet(M) and Tet(O), these proteins are able to unbind 
Tetracycline from its target rRNA and halt its action. The Tet(M) 37 also modifies the 
geometry of the binding site within the rRNA, prevent further interaction from the drug 
molecule. Tet(O) has a similar mode of action, but attacks the drug molecule itself, 
changing the structure of the molecules active site, and preventing binding with the rRNA 
substrate. 
FIGURE 12 ± CROSS SECTION OF AN E. COLI CELL MEMBRANE, SHOWING THE  
STRUCTURE AND FUNCTION OF AN RND EFFLUX PUMP, SHOWING HOW THEY USE 
PROTONS AND SUBSTRATE MOLECULES. 65 
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Modifications of the microbial target sites are very common resistance mechanisms 
employed by bacteria. These target modifications can exist as; point mutations in the genes 
that code for the target sites, modification of the binding site itself via enzymes, or total 
replacement and bypassing of the original target site. 
Point mutations in the genetic code of the target site cause the expression of different 
proteins at various points along the peptide that makes up its structure 38. This will slightly 
alter the superstructure of the site, meaning that it is no longer a conformational fit for the 
antibacterial molecule, rendering it ineffective. 
Enzymatic modification of the target sites can also occur, for example, erm genes 
(Erythromycin Ribosomal Methylation) 39 cause macrolide resistance within aerobic, 
anaerobic, Gram-positive and Gram-negative bacteria by bonding one or two methyl 
groups onto an adenine residue contained within the 50s subuQLWRIFHOO¶VULERVRPHV7KLV
prevents the drugs from being able to form complexes with the ribosome subunits to inhibit 
the cells protein synthesis. 
The most common example of complete target replacement is resistance within MRSA 
strains, they have been able to develop analogues of the old target sites that perform similar 
intracellular functions. Another antibacterial bypass is overexpression of the target sites 
within the cell, this meant that the antibacterial compound will still bind to its target sites, 
but due to the large number of targets produced, the cell will be able to continue its 
processes unhindered 32. 
 Membrane Differences 
Both bacteria and eukaryotes contain glycerol as the chief component in their phospholipids 
40
. The phospholipids usually contained within bacterial cells: (PS) - Phosphatidylserine, 
(PE) - Phosphatidylethanolamine, and (PG) - Phosphatidylglycerol, are also contained 
within eukaryotes. PG is a large component of Gram-positive bacterial cell membranes, 
and another (smaller) component of Gram-negative bacterial cell membranes (Figure 13) 
25 
 
(It is also a main component in mammalian pulmonary surfactant). Mammalian Cell 
membranes contain a similarly structured 'alternative' to the PG phospholipid - (PC) ± 
Phosphatidylcholine 41±43. 
 
FIGURE 13 - CHART COMPARING MEMBRANE COMPOSITION OF VARIOUS CELLS (KEY - (PE) - 
PHOSPHATIDYLETHANOLAMINE, (PG) - PHOSPHATIDYLGLYCEROL, (CL) CARDIOLIPIN, (PC) 























 Current Antibacterial Testing Methods 
Generally, the current methods of screening novel antibacterials are based around diffusion 
44
. The literature standard method of primary screening novel antibacterials is the Kirby 
Bauer disc diffusion method. The other diffusion based protocol is the well diffusion screen. 
These methods of antibacterial screening are effective for compounds that diffuse freely 
WKURXJKPDWHULDOVFRPSRXQGVWKDWGRQ¶WGLIIXVHDVUHDGLO\KDYHVHYHUHSUREOHPVZLWKIDOVH
negatives. For example, compounds like the ones being tested in this thesis that readily 
form hydrogen bonds during processes like self-assembly do not diffuse through agar, or 
off cellulose filter paper discs. This is because agarose and cellulose are materials rich in 
hydrogen bond forming functionalities, the potential antibacterials are forming hydrogen 
bonds with the materials in preference to diffusing off/through it. The disc diffusion assay 
is described in literature as the reliable testing method for screening antibacterials 45±47, 
however, tests carried out last year by a third year project student showed its 










FIGURE 44 - RESULTS OF EXPERIMENT SHOWING FALSE NEGATIVES PRODUCED BY KIRBY BAUER DISC 
DIFFUSION TEST, THE COMPOUND MARKED WITH THE ASTERISK IS THE SAME COMPOUNDS THAT IS BEING 
DROP TESTED ON THE RIGHT-HAND PLATE. THE DISC ASSAY PRODUCED NEGLIGIBLE RESULTS, WHEREAS THE 
DROP TEST ASSAY SHOWED THAT THE COMPOUND WAS VERY EFFECTIVE.  
1.8.1 Kirby Bauer Disc Diffusion 
To perform this assay, an agar plate is inoculated with a standardised volume of bacterial 
strain, the bacteria is spread with a sterile bar, and the plate is left to dry in sterile conditions. 
Once the plate is dry, sterile discs of filter paper impregnated with the test compounds are 
placed onto the plate surface before the plate is incubated 48,49. The zones of inhibition 
produced after incubation are measured and recorded.  
1.8.2 Well Diffusion 
To perform this assay, the molten agar is inoculated with a standardised volume of bacterial 
strain. The agar is then poured into a sterile petri dish. After the agar has set, a cutter is 
used to remove plugs of agar material to create wells. A standard volume of drug solution 
is added to each well, and the plate is incubated 50,51. 
 Development of New Screening Method 
The propensity of current antibacterial testing methods to produce false negatives has led 
to a need for the development of a new screening procedure, taking and adapting 
methodology from existing assays. The drop test assay was produced, the sterile agar plate 
is inoculated with a standardised volume of bacterial strain, the bacteria is spread with a 
sterile bar, and the plate is left to dry in sterile conditions. After the plate has dried, a 10µl 
droplet of compound solution is administered to the plate using a micropipette or a Hamilton 
syringe. This assay eliminates the diffusion element of the standard antibacterial screens 
by placing the compound in direct contact with the bacterial lawn. The drawbacks of the 
assay are that it is very difficult to produce completely uniform repeatable droplets 
manually, this could lead to exaggerated antibacterial effects shown if the droplet spreads 




 The compounds 
The compounds tested within this thesis belong to a family of novel supramolecular 
amphiphilic salts, first discussed by J. Hiscock et al in 2016 52. These salts consist of a 
hydrogen bond donating functionality, bookended either side by a lipophilic and a 
hydrophilic functionality. This is the part of the compound that provides the functionality. In 
addition to this structure, a countercation consisting of a tetraalkylammonium balances out 

























FIGURE 15 ± STRUCTURE OF THE ANTIBACTERIAL COMPOUNDS TESTED WITHIN THIS THESIS 
 
These compounds readily form and receive hydrogen bonds, allowing them to interact with 
each other. These interactions allow them to self-assemble, forming structures such as 
dimers, tapes, and two modes of stacking, Anti and Syn. (Figure 16) These binding modes 
cannot all exist at the same time, OHDGLQJWRDµIUXVWUDWHGV\VWHP¶. The mode of binding that 
is exhibited by a system relies on the balance of all the other binding modes existing within 
the contained solvent system. 
 
FIGURE 16 - DIGITAL RENDERING OF DIFFERENT BINDING MODES FORMED BY THE COMPOUNDS TESTED 





 Novel Amphiphillic Antibacterials 
Amphiphilic compounds have been recently investigated as antibacterial agents with lower 
probability of placing selection pressures on bacteria, causing the development of 
resistance. Membrane-targeting antibacterials have this reduced probability, as it would 
require a multi-generational timeframe for bacteria to recalibrate their complete membrane 
structure 53. 
In recent studies, amphiphillic compounds containing polar head groups and hydrophobic 
functionalities, have been investigated as novel antibacterials. Amphiphilic compounds are 
able to self-associate through stabilising supramolecular interactions; forming hydrogen 
bonds that link monomers into a nanostructure. Interactions between these amphiphilic 
compounds and bacterial cell membranes have been alluded to the interactions of 
membranes and surfactant detergents 54. In polar solvents, these amphiphiles can self-
associate to form micelles and bilayers. These aggregate structures have been proposed 
to interact with and disrupt cellular membranes, causing lysis, and eventually, complete cell 
death.  
Recent studies have developed several different families of amphiphile based compounds 
that have been shown to interact with bacterial cell membranes and cause cell lysis 53±56. 
These compounds are the closest in structure and theoretical action to the compounds 




 MIC  
The MIC of a compound is the Minimum Inhibitory Concentration. This refers to the 
percentage of bacterial growth that is susceptible to inhibition from the compounds 44. This 
DVVD\LVFRQVLGHUHGWKHµJROGVWDQGDUG¶RIantibacterial susceptibility testing, and is used to 
confirm activity of novel compounds, especially when diffusion methods such as Kirby 
Bauer and Etesting DUHQ¶WFRPSDWLEOHZLWKWKHPRGHRf activity. The standard method of 
calculating the MIC of a compound is the broth microdilution method. The procedure for 
this assay involves placing serially diluted concentrations of the drug being tested into 
sterile tubes. The tubes are then inoculated with a set volumes of standardised bacterial 
suspension. These drug and bacterial suspensions are then used to inoculate fresh agar 
plates. The plates are then incubated overnight to promote bacterial lawn growth, and the 
MIC value of the compound is calculated from the plates on which the bacterial lawn has 
not grown 57. There is also an assay for determining MIC by broth microdilution 58. Whilst 
QRWDµJROGVWDQGDUG¶RIVXVFHSWLELOLW\WHVWLQJLWLVVWLOOZLGHO\XVHGZLWKLQPLFURELRORJ\8VLQJ
this method would overcome the diffusion issues posed by other methods, however, the 
newly developed plate reader assay has several advantages over it. These are time and 
the raw results produced. The broth dilution assay is incubated for 24 hours before the 
plates are examined, whereas the plate reader assay is run for a period of 15 hours, with 
most of the results being produced well before, and up to the 12-hour mark, making it twice 
as quick as the broth assay. The results produced by the plate reader assay can then be 
processed and plotted to form quantifiable graphs, whereas, the broth microdilution results 





2 Materials and Methods 
 Bacterial Cultures: 
Cultures of S. aureus and E. coli were stored at -80 °C in glycerol. The fr eezer stocks of 
bacteria were prepared by adding 0.85 mL of bacterial culture to 0.15 mL of autoclave 
sterilised glycerol, to produce a final concentration of 15%. The culture and glycerol solution 
was then vortexed to produce an even mixture, before being transferred to a storage tube. 
The tube was then labelled and frozen in liquid nitrogen, and moved into -80 °C freezer for 
storage. Bacterial strains were streaked out onto fresh LB agar plates (5 g Yeast Extract, 
10 g Tryptone, 10 g Sodium Chloride, 15g Agar, 1 L deionised water) in sterile conditions 
to isolate single colonies. Under sterile conditions, these colonies were picked with a sterile 
pipette tip, and transferred into a universal tube the bacteria cell cultures were then grown 
using standard lab protocols in 37°C incubators. 
 Testing methods:  
The structure and composition of the compounds being tested gives rise to moieties that 
can donate and accept hydrogen bonds. This allows the compounds to form hydrogen 
bonds with itself, creating structures such as micelles, vesicles and tapes. This 
characteristic forming of hydrogen bonds means that the literature standard testing 
methods such as Kirby Bauer disc diffusion and well diffusion are not effective methods of 
screening the compounds referred to in this thesis. The Kirby Bauer and well tests use 
cellulose based filter papers and agarose agar respectively, and these two materials 
contain many hydrogen bond donating functionalities7KHFRPSRXQGVDUHQ¶WDEOHWRGLIIXVH 
properly off the paper and through the agar, leading to an inaccurate result showing 
antibacterial activity. These false negative results lead to the development of a new assay, 
drop testing, and an automated way of carrying out the testing, the Rapid Antibacterial 
Susceptibility Screener ± R.A.S.S. 
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 Drop Test solution preparation: 
The solution for the drop testing assay was prepared by dissolving a set mass of compound 
in 5% in either 2.5, 5 or 10ml of 5% ethanol solution (5ml ethanol and 95ml deionised 
water). The solutions were then vortex mixed to ensure the solid was dissolved and the 
vials were then Parafilmed® to prevent evaporation of the solution. It should be noted that 
neither the urea or the thiourea tetrapentylammonium compounds were able to dissolve in 
any of the biocompatible solutions tested. 
 Drop testing: 
200µl of bacterial culture were pipetted onto a fresh agar plate, spread with a sterile glass 
spreader bar, and allowed to dry, as per the standard literature method. The compound 
solutions were then dropped onto the dry plate using a 50 ȝ/Hamilton® syringe; needle 
size 22s ga (bevel tip), needle L 51 mm (2 in.) The plates were placed into an incubator 
and incubated at 37°C overnight to allow growth of the bacterial lawn, and theoretical  
antibacterial action of the compounds producing a zone of inhibition. After incubation, the 









 McFarland Standard Solution Preparation 
The McFarland solutions (Figure 17) for calibration and standardisation of the 
spectrophotometers were prepared by adding volumes of 1% sulphuric acid to 1% barium 
chloride. (Table 1) 
 
FIGURE 17 - SET OF SYNTHESISED MCFARLAND STANDARDS, SHOWING THE GRADIENT OF OPTICAL 
DENSITIES PRODUCED 
 
McFarland Standard No. 0.5 1 2 3 4 5 6 
1.0% Barium chloride (ml) 0.05 0.1 0.2 0.3 0.4 0.5 0.6 
1.0% Sulphuric acid (ml) 9.95 9.9 9.8 9.7 9.6 9.5 9.4 




FIGURE 18 - GRAPH SHOWING THE MEASURED VALUES FOR THE MCFARLAND STANDARD 
SPECTROPHOTOMETER CALIBRATION ASSAY 
 
FIGURE 19 - GRAPH SHOWING THE THEORETICAL VALUES FOR THE MCFARLAND STANDARD 
SPECTROPHOTOMETER CALIBRATION ASSAY 
 
The prepared McFarland Standards were scanned at 595nm on a spectrophotometer to 
produce calibration curves for the standardisation of the optical density of the bacterial 
suspension used in assays. (Figure 18-19) 
 MIC50 Assay ± 96 well plates:  
Bacteria was cultured in Luria Broth (LB) media and incubated at 37ºC until in mid-log 
phase. The culture was then diluted to an optical density of 0.75 ABS using a 
spectrophotometer calibrated using the McFarland standards. The MIC50 assay was 
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prepared by adding 50µl of the cell culture in media to each well of a sterile 96 well F-
bottom Greiner UV-Star® plate using a HandyStep® Electronic Repeating Pipette. After the 
culture was added, 10µl of the drop test solutions were added to each well. (Figure 20) The 
plates were then Parafilmed® to prevent evaporation of the solution. The plates were then 
placed into the spectrophotometer (Thermo 6FLHQWLILF 0XOWLVNDQ GO Microplate 
Spectrophotometer), and optical density readings were taken at 595nm, at a time interval 









 Tetraalkylammonium activity screen 
The tetraalkylammonium compounds were tested using exactly the same procedures as 
the MIC50 assay described above, using solutions of the four tetraalkylammonium 
hydroxide compounds  
 NMR Spectroscopy  
The NMR spectroscopy for the compounds synthesised was carried out on a Jeol ECS-
400 spectrometer. All chemical shifts were reported in parts per million (ppm), and the 
spectra were calibrated to the peak produced by a deuterated solvent (Deuterated solvents 
FIGURE 20 - 96 WELL PLATE LAYOUT USED FOR ASSAY. 
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purchased from Cambridge Isotope Laboratories Inc.). The spectra were analysed using 
ACD/NMR Processor Academic Edition. (Version 12.01) 
 3D Design of Robot Parts 
The parts for the R.A.S.S. system were designed within Sketchup Make 2017 59 (Version 
17.2.2555 64-bit copyright Trimble Inc. 2016) using the 3D printing mm template. After a 
component was finished, is was exported from Sketchup as a Sterolithography file (.stl). 
The .stl file was then imported in CURA 60 (Version 2.3.1 Copyright Ultimaker B.V. 2017) 
and optimised for printing. Once the model had been sliced, checked and optimised in 
CURA, it was exported from the program as a G-Code file. The G-code file was then 
transferred to an SD card, which was then inserted into the 3D printer. 
  3D Printing and Assembly of Robot Parts 
Once the SD card was inserted into the printer, the component file was selected in the on-
board menu and the print was executed. All components were printed on an Ultimaker 2+ 
with a layer height of 0.1mm, a wall thickness of 1.0mm, a top and bottom wall thickness 
of 1.0mm, an infill density of 20%, a print speed of 60mm/s, a travel speed of 120mm/s, 
cooling enabled, the fan speed manually set to 75%, and a build plate adhesion skirt printed 
to secure the model. The plastic used was RS Pro black PLA 1.75mm, purchased from RS 
components. The cage assembly was constructed from lengths of RS Pro Aluminium Alloy 
Strut 20 x 20, 5mm Groove (4x500mm and 8x200mm), fastened together with Countersunk 
Head Machine Screws, M5 x 40mm, Bright Zinc Plated, Clear Passivated Steel. Loctite 
universal superglue was used to weld components together. 
 Incorporation of Lego Parts 
The actuator and motor components are manufactured by The Lego Group, the linear 
actuator (Part number 61927c01) was sunk into the syringe block and glued into place, with 
a Mindstorms NXT motor (Part number 53787) glued into place on the bottom of the stage 
and coupled up to the actuator. A small LEGO Technics rail was glued to the top of the 
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stage assembly and a medium Mindstorms EV3 motor (Part number 99455) was attached 
to it. This motor was coupled to a LEGO Technic 24 tooth gear wheel (Part number 24505). 
This tooth gear was coupled to the 3D printer tooth rail part of the lowering mechanism 
assembly. The lowering and syringe drop mechanism was then attached to a frame 
consisting of two T-profile geared rails and endcaps. This whole assembly was attached to 
the X-Movement structure via two geared interfaces (consisting of a large EV3 motor ± Part 
number 95658, and two more 24 tooth gear wheels joined by a LEGO Technic axle), this 
created the Y-Movement assembly. The X-Movement structure was powered by two more 
Mindstorms NXT motors. The wiring was constructed by taking the stock LEGO Mindstorms 
connector cables (Part number bb601), stripping them to expose the 6 core wires, and 




















































 Robot Code 
The program for the robotic testing system was executed by two LEGO Mindstorms 
controller bricks, one NXT and one EV3 (Part numbers 9841 and 45500). The EV3 brick 
controlled the Y movement, the stage lowering, and the syringe plunger actuator. The NXT 
brick controlled the X movement of the whole assembly.  
The program was written in the LEGO Mindstorms EV3 home edition 61(Version 1.2.2 Build 
20161007.4 Copyright The Lego Group 2013) with one file containing the program for 
controlling the X movement loaded onto the NXT brick, and another file containing the 
program for controlling all of the other processes. The problem faced with these two 
programs was that since the NXT brick is from a previous generation of hardware, the EV3 
EULFNZDVQ¶WDEOH WRFRPPXQLFDWHZLWK LW7KLV OHDG WR WKH WZRVHSDUDWHSURJUDPVEHLQJ
developed, with the process commands separated by time delay buffers. This allowed both 
programs to be executed without interfering with each other and causing damage to the 
dropping mechanism, as failed programs bent the dropping needle by starting the X 
movement whilst it was still sunk into a well. 
 Setting up the Sampling Rack and Loading a Plate 
The sample rack attached to the frame of the robot is loaded with 15 samples and an 
ethanol wash. The liquids were contained within 2.0ml Eppendorf tubes, with the ethanol 
tube loaded into the (1,1) co-ordinate of the rack, as that is where the needle assembly will 
home to at the end of each drop cycle. A squat glass vial is loaded into the waste disposal 
section of the sample rack. The plate stage interface has 3 interchangeable plate caddies, 
fitting standard 95mm petri dishes, large diameter 200mm petri dishes, and 96 well plates. 
 
 Pyridinium Salt 
4-(Trifluoromethyl) phenyl isocyanate (0.268g) was added to a stirring solution of 
aminomethanesulfonic acid (0.416) in anhydrous pyridine (15 mL) under an inert 
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atmosphere. The mixture was heated to 60 °C for four hours. The pyridine was the n 
removed by filtration. Yield: 0.378g (55%) 
 Tetrapentylammonium Salt 
Solution of tetrapentylammonium hydroxide (1.8ml) was added dropwise to pyridinium Salt 
(0.360 g) in chloroform (10 mL) and washed with water (50 mL). The organic fraction was 
then taken to dryness to give the pure product as a white solid. Yield: 0.276g (76%) 
 Tetrahexylammonium Salt 
Solution of tetrapentylammonium hydroxide (1.9ml) was added dropwise to pyridinium Salt 
(0.360 g) in chloroform (10 mL) and washed with water (50 mL). The organic fraction was 




 Analysis of False Negative Disc Assay Results 
The Kirby Bauer disc diffusion assay was not used for the compounds tested in this thesis. 
A third year project student performed an analysis of the assay, measuring the diffusion of 
the compound off of the filter paper discs. The results obtained show the hydrogen bonding 
association between the paper discs and the compounds has an adverse effect on the 
ability of the compounds to diffuse off of them and cause zones of inhibition, needing a 
greater concentration of compound contained within the disc to produce the zone of 
inhibition that would be observed with a lower concentration without the disc hindrance. 
This leads to false negative results when performing the assay.  
These false negatives were the reason that the drop testing assay was developed, 
removing the need for the filter paper interface, and therefore removing the diffusion 
hindrance. This allowed the compounds to be applied directly to the bacterial lawn, allowing 
the potential antibacterial effect to be observed more accurately. (Research Credit to Tom 
Runacres) 
 Validation of growth curve assay with clinically available 
antibacterials 
MIC values of compounds were calculated using the growth curve assay developed during 
this project. This assay measured the optical density of bacterial suspensions contained 
within sterile 96 well plates every 15 minutes for a total of 17 hours. Each numerical column 
on the plate was a series of 8 repeats of varying concentrations of the compound being 
tested. After the data was collected, it was copied into a spreadsheet that split the 
concentration repeats, plotting them into 12 separate graphs. This allowed the data to be 
analysed and outliers to be removed. The remaining data was then averaged and the final 
growth curve could be plotted. The endpoint optical densities were then taken from the time 
of 15 hours (900 mins). 
The assay described above for calculating the MIC50 values of antibacterials was validated 
by another Masters project student within the group, performing it with commercially 
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available drugs, and comparing the resultant values with literature values. The 
antibacterials used were Ampicillin and Vancomycin, and as with the novel compound 
testing, the bacteria used were S. aureus and E. coli. Exactly the same procedure was 
used on the established antibacterials, and the novel compounds. All solutions were 
dissolved within 5% ethanol. 
The MIC50 values of vancomycin were calculated against S. aureus in stationary growth 
phase at the seven hour (420 min) (Figure 22) This is where the compound exhibited its 
antibacterial activity. Using the growth curve assay the MIC50 value of Vancomycin was 
calculated to be around 0.99 µg/ml which is in between the literature values of 0.5-2.0 
µg/ml. (Research Credit Laura Blackholly) 
 






























Vancomycin against Stationary Phase S. 
aureus











3 Results  
 
1H NMR  spectrum of Tetrapentylammonium Compound 
Once the tetrapentylammonium compound was synthesised, it was dried and analysed by 
NMR spectroscopy. This analysis produced the spectrum visible below, showing the 
compound was present, clean and in the correct ratios. 
 





1H NMR spectrum of Tetrahexylammonium Compound 
Once the tetrapentylammonium compound was synthesised, it was dried and analysed by 
NMR spectroscopy. This analysis produced the spectrum visible below, showing the 
compound was present, clean and in the correct ratios. 
 




 MIC50 Assay Results 
All of the MIC50 results were collected and analysed within a Microsoft Excel worksheet, 
this produced the raw growth curve graphs (These are the coloured graphs). The 
endpoint optical densities at 900 minutes were then taken for each concentration of 
compound and entered into Origin. These values were then plotted and fitted (These are 
the red-lined graphs). The data for the compounds producing antimicrobial effects against 
Gram-Positive bacteria were fitted with sigmoidal curves, with the cutoff in the graph 
giving the MIC50 values. The data for the compounds producing antimicrobial effects 
against Gram-Negative bacteria were fitted with linear curves, with the midpoint of the 
graph giving the MIC50 values.  
The MIC values calculated from these datasets was collated, producing the table at the 
end of this section 
The compounds were assayed against bacteria in different phases of growth, logarithmic 
(log) and stationary. During log phase the bacteria are rapidly reproducing, so the 
population exponentially increases, and during stationary phase, the growth rate of the 
bacteria levels out, producing a stable population. In addition to this, the morphology of 
the cell wall changes, so testing during this phase is needed, as the results will be 








3.3.1 Urea Based compound family with Log S. aureus 
These compounds were found to be the most effective against the Gram-positive S. 
aureus bacteria, with all variants tested producing results. All of the Origin plots showed 
sigmoidal fits. 
   
































FIGURE 23 ± GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED TETRAMETHYLAMMONIUM 

































Urea Base with Tetramethylammonium 





















































FIGURE 24 - GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED TETRAETHYLAMMONIUM 

































Urea Base With Tetraethylammonium 
















































FIGURE 25 - GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED TETRAPROPYLAMMONIUM 

































Urea Base With Tetrapropylammonium 














































FIGURE 26 - GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED TETRABUTYLAMMONIUM 

































Urea Base With Tetrabutylammonium 






















































FIGURE 27 - GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED TETRAHEXYLAMMONIUM 
































Urea Base With Tetrahexylammonium 















3.3.2 Thiourea Based compound family with Log S. aureus 
These compounds were found to be ineffective against the Gram-positive S. aureus 
bacteria, with only the tetrabutylammonium variant tested producing a result. The Origin 
plot showed a sigmoidal fit.  
 




































Thiourea Base With 















FIGURE 29 - GROWTH CURVE FOR THIOUREA BASED TETRAETHYLAMMONIUM COMPOUND AGAINST LOG S. 
AUREUS  
 




































Thiourea Base With Tetraethylammonium 














































Thiourea Base With Tetrapropylammonium 

















































FIGURE 61 - GROWTH CURVE AND ORIGIN MIC PLOT FOR THIOUREA BASED TETRABUTYLAMMONIUM 



































Thiourea Base With Tetrabutylammonium 















3.3.3 Urea Based compound family with Log E. coli 
These compounds were found to be ineffective against the Gram-negative E. coli 
bacteria, with only the tetrahexylammonium variant tested producing a result. The Origin 
plot showed a linear fit.  
 


































Urea Base with Tetramethylammonium 















FIGURE 33 - GROWTH CURVE FOR UREA BASED TETRAETHYLAMMONIUM COMPOUND AGAINST LOG E. COLI  
 
































Urea Base with Tetraethylammonium 











































Urea Base with Tetrapropylammonium 












































Urea Base with Tetrabutylammonium 















































FIGURE 36 - GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED TETRAHEXYLAMMONIUM 
































Urea Base with Tetrahexylammonium 














3.3.4 Thiourea Based compound family with Log E. coli 
These compounds were found to be ineffective against the Gram-negative E.coli bacteria, 




FIGURE 37 - GROWTH CURVE FOR THIOUREA BASED TETRAMETHYLAMMONIUM COMPOUND AGAINST LOG 
































Thiourea Base with 















FIGURE 38 - GROWTH CURVE FOR THIOUREA BASED TETRAETHYLAMMONIUM COMPOUND AGAINST LOG E. 
COLI  
 
FIGURE 39 - GROWTH CURVE FOR THIOUREA BASED TETRAPROPYLAMMONIUM COMPOUND AGAINST LOG 


























Thiourea Base with Tetraethylammonium 











































Thiourea Base with Tetrapropylammonium 


























































Thiourea Base with Tetrabutylammonium 














3.3.5 Urea Based compound family with Stationary S. aureus 
These compounds were found to be the most effective against the Gram-positive S. 
aureus bacteria, with all variants tested producing results. All of the Origin plots showed 
sigmoidal fits. 
 

































































Urea Base With Tetramethylammonium 












FIGURE 41 - GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED 



































FIGURE 42 - GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED TETRAETHYLAMMONIUM 


































Urea Base With Tetraethylammonium 


















































FIGURE 43 - GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED TETRAPROPYLAMMONIUM 
































Urea Base With Tetrapropylammonium 



















































FIGURE 44 - GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED TETRABUTYLAMMONIUM 

































Urea Base With Tetrabutylammonium 


















































FIGURE 45 - GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED TETRAHEXYLAMMONIUM 
































Urea Base With Tetrahexylammonium 














3.3.6 Thiourea Based compound family with Stationary S. aureus 
These compounds were found to be ineffective against the Gram-positive S. aureus 
bacteria, with none of the variants tested producing results. No Origin plots were needed 
FIGURE 46 - GROWTH CURVE FOR THIOUREA BASED TETRAMETHYLAMMONIUM COMPOUND AGAINST 














































FIGURE 47 - GROWTH CURVE FOR THIOUREA BASED TETRAETHYLAMMONIUM COMPOUND AGAINST 
STATIONARY S. AUREUS 
FIGURE 48 - GROWTH CURVE FOR THIOUREA BASED TETRAPROPYLAMMONIUM COMPOUND AGAINST 
































Thiourea Base With Tetraethylammonium 



























































FIGURE 49 - GROWTH CURVE FOR THIOUREA BASED TETRABUTYLAMMONIUM COMPOUND AGAINST 











































Thiourea Base With Tetrabutylammonium 














3.3.7 Urea Based compound family with Stationary E. coli 
These compounds were found to be ineffective against the Gram-negative E. coli 
bacteria, with only the tetrabutylammonium variant tested producing a result. The Origin 
plot showed a sigmoidal fit.  
 
FIGURE 50 - GROWTH CURVE FOR UREA BASED TETRAMETHYLAMMONIUM COMPOUND AGAINST 































Urea Base With Tetramethylammonium 















FIGURE 51 - GROWTH CURVE FOR UREA BASED TETRAETHYLAMMONIUM COMPOUND AGAINST STATIONARY 
E. COLI 
 
FIGURE 52 - GROWTH CURVE FOR UREA BASED TETRAPROPYLAMMONIUM COMPOUND AGAINST 






























Urea Base With Tetraethylammonium 










































Urea Base With Tetrapropylammonium 




















































FIGURE 53 - GROWTH CURVE AND ORIGIN MIC PLOT FOR UREA BASED TETRABUTYLAMMONIUM 































Urea Base With Tetrabutylammonium 

























































Urea Base With Tetrahexylammonium 















3.3.8 Thiourea Based compound family with Stationary E. coli 
These compounds were found to be ineffective against the Gram-negative E.coli bacteria, 
with none of the variants tested producing a result. No Origin plots were needed for these 
results 
 
FIGURE 55 - GROWTH CURVE FOR THIOUREA BASED TETRAMETHYLAMMONIUM COMPOUND AGAINST 




































Thiourea Base With Tetramethylammonium 
















FIGURE 56 - GROWTH CURVE FOR THIOUREA BASED TETRAETHYLAMMONIUM COMPOUND AGAINST 
STATIONARY E. COLI 
 
FIGURE 57 - GROWTH CURVE FOR THIOUREA BASED TETRAPROPYLAMMONIUM COMPOUND AGAINST 































Thiourea Base With Tetraethylammonium 



























































FIGURE 58 - GROWTH CURVE FOR THIOUREA BASED TETRABUTYLAMMONIUM COMPOUND AGAINST 
STATIONARY E. COLI 
 Urea Base Thio Base 
MIC50 Log S. aureus Stat S. aureus Log E. coli Stat E. coli Log S. aureus 
  ʅŐ ?ŵ> ʅŐ ?ŵ> ʅŐ ?ŵ> ʅŐ ?ŵ> ʅŐ ?ŵ> 
Meth 0.45 5.58 N/a N/a N/a 
Eth 19.14 39.39 N/a N/a N/a 
Prop 21.60 10.64 N/a N/a N/a 
But 7.35 209.13 N/a 412.08 54.13 
Pent N/a N/a N/a N/a N/a 
Hex 29.08 464.14 237.00 450.99 N/a 
      
 Urea Base Thio Base 
MIC100 Log S. aureus Stat S. aureus Log E. coli Stat E. coli Log S. aureus 
  ʅŐ ?ŵ> ʅŐ ?ŵ> ʅŐ ?ŵ> ʅŐ ?ŵ> ʅŐ ?ŵ> 
Meth 2.97 7.30 N/a N/a N/a 
Eth 20.08 54.08 N/a N/a N/a 
Prop 22.68 10.92 N/a N/a N/a 
But 29.41 254.56 N/a 421.06 93.55 
Pent N/a N/a N/a N/a N/a 
Hex 30.35 559.13 505.67 480.25 N/a 
































Thiourea Base With Tetrabutylammonium 















3.3.9 The Tetraalkylammonium Chloride Salts with Log S. aureus 
These experiments were to prove which part of the molecule being tested produced the 
therapeutic effect, and as the tetraalkylammonium counteraction was not present, and 
none of the results yielded antimicrobial effect, this shows the counteraction is 
responsible for the activity of the compound. 
  


















































FIGURE 61 - GROWTH CURVE FOR TETRAETHYLAMMONIUM CHLORIDE COMPOUND AGAINST LOG S.AUREUS 
  































































































FIGURE 63 - GROWTH CURVE FOR TETRABUTYLAMMONIUM CHLORIDE COMPOUND AGAINST LOG S.AUREUS 
3.3.10 The Tetraalkylammonium Chloride Salts with Log E. coli 
  












































































































































FIGURE 66 - GROWTH CURVE FOR TETRAPROPYLAMMONIUM CHLORIDE COMPOUND AGAINST LOG E. COLI 
  




























































































 Results of the Robotic Drop Testing Method 
Despite the drawback of the two LEGO brick modules not being able to communicate with 
each other, the time delayed dual program procedure was effective, allowing the dropping 
mechanism to move freely from the sample block to the petri dishes. As the microliter 
syringe was electronically and mechanically controlled, it was able to produce and 
reproduce similar sized droplets on the surface of the plate. 
 





 Discussion of MIC Growth Rate Assay 
All the urea based compounds that were tested exhibited antibacterial activity against both 
log and stationary phase cultures of S. aureus, with the most prolific compound being the 
tetramethylammonium with an MIC50 value of 0.45µg/ml. As the chain length of the 
tetraalkylammonium countercation increases, the efficacy of the compound decreases, but 
the tetrabutylammonium compounds do not follow the trend, exhibiting the second highest 
MIC50 value of 7.35µg/ml. The tetrabutylammonium and tetrahexylammonium also 
exhibited an antibacterial effect against E. coli, with the hexyl compound producing MIC 
values for both log and stationary phase cultures, and the butyl producing an MIC value for 
stationary phase culture. The butyl still exhibited antibacterial action against the E. coli 
cultures, but higher concentrations of drug need to be tested to give a clear calculation for 
the MIC values. (Figure 26-39) 
All the thiourea based compounds except one were ineffective as antibacterials. Only the 
Tetrabutyl countercation exhibited an antibacterial effect, producing an MIC50 value of 
54.13µg/ml against S. aureus in log phase. However, the compound did not exhibit the 
same effect against stationary phase, meaning higher concentrations will need to be 
investigated in further experimentation. None of the thiourea compounds were effective 
against the cultures of E. coli 
All compounds tested within this thesis exhibited an effect when added to bacterial 
suspensions, when an antibiotic effect is not produced, the compounds exhibit an increase 
in the optical density of the suspension, this effect is hypothesised to be caused by the 
compounds self-associating to form aggregated nanostructures within the solution, or the 
association of the compounds with the cell membranes of the bacteria within the solution. 
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 Discussion of Tetraalkylammonium Hydroxide Compounds 
The tetraalkylammonium compounds were tested with the exact same protocols as the 
urea and thiourea based compounds tested within this thesis. This was to investigate which 
functional part of the molecule produced the antibacterial effect. In all the experiments 
performed, none of the tetraalkylammonium compounds exhibited antibacterial effects. All 
of the compound experiments exhibited an increase in the measured optical density of the 
bacterial suspensions, this was hypothesised to be caused by the self-association of the 
compounds, either causing aggregate structures within the solution, or aggregating around 
the membranes of the cells. This shows that the compounds either cause, or add to the 
increase in optical density, but do not contribute anything to the antibacterial effect of the 
compounds. 
 Discussion of the Robotic Drop Testing Method 
Improvements for the system can be made, with the replacement of the NXT brick being 
replaced with the newer EV3 brick being the first step, allowing one program to be 
developed to control all of the motor functions of the robot. The final upgrade for the 
R.A.S.S. system is a complete replacement of all the motors and control system with 
component stepper motors and an electronic control unit powered by a microcomputer such 
as an Arduino board or a Raspberry Pi. This component overhaul would allow the actions 
of the robot to be even more customisable as stepper motors have much more accurate 
rotary encoders, allowing finer control of the needle positioning. 
5 Conclusion and further work 
The aim of this thesis was to investigate the testing methods for synthesised antibacterial 
compounds, and then apply these assays to a family of novel amphiphilic compounds. The 
investigation took the data from previously performed experiments concerning the reliability 
and accuracy of the Kirby Bauer disc diffusion assay, and used this information to develop 
the drop testing assay. This assay prevented false negative results within the compound 
screens performed, however suffered from limited repeatability due to the intricate process 
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of the manual addition of microliter droplets of solution onto an agar plate. This led to the 
development of the R.A.S.S. system, this modular robot allowed the precise dropping of 
solutions onto agar plates in an automatic and repeatable protocol. The robot can be 
programmed to dispense completely customisable grids of solution droplets on standard 
and large form petri dishes, with scope for a program that will automatically dose a 96 well 
plate. 
After a screening protocol was developed, the MIC assay was investigated, the information 
gathered using this procedure was used to calculate the MIC values of the novel family of 
amphiphilic compounds. The methodology was validated by using the assay to calculate 
the value of known and clinically available antibacterial compounds. 
The compounds investigated all exhibited effects against both Gram-positive and Gram-
negative bacteria, either antibacterial effects, inhibiting the growth of the pathogenic cells 
(Gram-Positive), or increasing the optical density through forming aggregated structures 
(Gram Negative). The antimicrobial effects observed are also comparable to currently 
available clinical compounds, with the MIC50 value of 0.45 µg/ml for the Urea based Methyl 
compound competing with the values of 1 µg/ml and 2 µg/ml for Vancomycin and Amoxiclav 
respectively, and the MIC50 value of 7.35 µg/ml for the Urea based Butyl compound 
competing with the value of 8 µg/ml for Erythromycin. 
Further investigation of this family of compounds is needed, particularly microscopy, this 
would confirm the mode of action of the self-association, showing whether the aggregate 
structures are free in solution of interacting with the bacterial cell membranes. After this, 
testing of the compounds on clinical bacterial strains such as the ESKAPE pathogens 
should also be investigated as well as further testing into the antibacterial mode of action. 




6 Appendix ± ESI 
 Tetrapentylammonium Compound 
Melting Point: 90 ºC; 1H NMR (400 MHz, DMSO-Gį0.88 (t, 3H), 1.28 (m, 2H), 1.56 (s, 
4H), 3.15 (t, 2H), 3.93 (d, 2H), 6.94 (s, 1H, NH), 7.55 (m, 4H) 9.24 (s, 1H, NH); 13C{1H} 
NMR (100 MHz, DMSO-d6): į: 56.38 (CH2), 117.61 (CH), 121.16 (C), 121.48 (CH), 
123.83 (C), 126.29 (C) 126.53 (C) 144.77 (C), 154.70 (C); ,5ILOPȞ 3278 (NH stretch), 
2964, 1544, 1321, 1161, 840; HRMS for (C29H52F3N3O4S) (ESI-): m/z: act: 297.0155 [M-









IR spectrum of Tetrapentylammonium Compound 
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 Tetrahexylammonium compound 
Melting Point: N/a ± Compound is an oil; 1H NMR (400 MHz, DMSO-d6): į: 0.83 (m, 3H), 
1.24 (d, 2H), 1.52 (m, 2H), 3.11 (m, 2H), 3.87 (d, 2H), 6.85 (s, 1H, NH), 7.48 (m, 4H) 9.28 
(s, 1H, NH); 13C{1H} NMR (100 MHz, DMSO-d6): į: 56.41 (CH2), 117.62 (CH), 117.62 
(CH), 121.30 (C), 126.24 (CH), 126.26 (C) 126.28 (CH) 144.82 (C), 154.76 (C); IR (film): 
Ȟ 3288 (NH stretch), 1695, 1222, 1111, 840; HRMS for (C33H60F3N3O4S) (ESI-): m/z: 
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